To date, aside from HER2 expression status and genetic biomarkers, no reliable predictive blood biomarker for anti-HER2 therapies has been validated for clinical use in patients with HER2-positive breast cancer treated with trastuzumab [26–28]. The gene discussed is ERBB2; the disease is breast cancer.